Neo Ivy Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Neo Ivy Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-90,364	Closed	-$810K	–	394
2025 Q2	$810K	Buy	+90,364	New	+$842K	0.26%	136
2022 Q4	$188K	Buy	+16,386	New	+$204K	0.13%	231
2022 Q2	–	Sell	-466	Closed	-$8K	–	407
2022 Q1	$8K	Buy	+466	New	+$7.47K	0.01%	440
2021 Q3	–	Sell	-17,543	Closed	-$277K	–	465
2021 Q2	$277K	Buy	17,543 +3,084	+21%	+$41.9K	0.28%	134
2021 Q1	$147K	Buy	+14,459	New	+$149K	0.16%	198

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neo Ivy Capital Management's BCRX Position: Q3 2025 in Review

Neo Ivy Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 90,364 shares — an estimated $810K sold.

Neo Ivy Capital Management first reported a position in BCRX in Q1 2021 and held it in 5 quarters. The position peaked at $810K in Q2 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

Neo Ivy Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Neo Ivy Capital Management sold 90,364 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $810K.
Neo Ivy Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Neo Ivy Capital Management's BioCryst Pharmaceuticals position peaked at $810K in Q2 2025.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Neo Ivy Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.